13-valent pneumococcal conjugate vaccine not checked
Pfizer · 13vPnC · 13-valent Pnumococcal Conjugate vaccine
FollowEvery change as it happens, and a Monday email
Trials
2 active
22 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pneumococcal Diseases, Pneumococcal Disease
- Main trialPhase 3
- “The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants. It will also evaluate if the study vaccine can help the body make antibodies (known as immune response). These antibodies help protect against 20 types of pneumococcal bacteria. The study will compare 20vPnC with 13vPnC (control vaccine), which is approved for use in infants. The study is seeking participants who: * Are healthy infants * Aged 42 to 98 days of age at the time of consent. Infants…”In the company’s words, NCT07754539 on ClinicalTrials.gov
- Other names
- 13vPnC · 13-valent Pnumococcal Conjugate vaccine
Other drugs for Pneumococcal Diseases
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- PG4Pfizer · Phase 3
- Pneumococcal conjugate vaccinePfizer · Phase 3
- PrevnarPfizer · Phase 3
Coming up2
- 10 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials22
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Nov 2028 | A Study to Evaluate 20vPnC in Healthy Chinese Infants | |
| Phase 1Active, not recruiting | 10 Jun 2027 | A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | |
| Phase 4Completed | 30 Nov 2022 | A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India | |
| Phase 3Completed | Oct 2009 | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India | |
| Phase 3Completed | 16 Dec 2009 | Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine | |
| Phase 3Completed | 13 Jan 2010 | Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan | |
| Phase 3Completed | 10 Aug 2010 | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years | |
| Phase 3Completed | 1 Aug 2011 | Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults | |
| Phase 3Completed | Apr 2014 | A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China | |
| Phase 3Completed | 16 Dec 2019 | Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults | |
| Phase 3Completed | 12 Feb 2020 | Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination | |
| Phase 3Completed | 23 Aug 2021 | A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children | |
| Phase 3Completed | 2 Apr 2022 | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants | |
| Phase 3Completed | 22 Apr 2022 | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants | |
| Phase 3Completed | 13 May 2022 | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan | |
| Phase 3Completed | 31 Aug 2022 | 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants | |
| Phase 3Completed | 2 Sep 2022 | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants | |
| Phase 3Completed | 1 Jun 2023 | Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 | |
| Phase 3Completed | 20 Sep 2025 | A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan | |
| Phase 2Completed | 11 Feb 2020 | Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants | |
| Phase 1Completed | 7 Oct 2022 | Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age | |
| Phase 1Completed | 28 Jan 2026 | A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026